The Department of Hematology and Cell Therapy is one of the earliest established clinical departments at SRRSH. The Department of Hematology and Cell Therapy was established based on the hospital's development goal of being more specialized,  innovative and advanced. The department focuses on the diagnosis and treatment of common hematological diseases as well as rare and challenging disorders. We have  rich clinical experience in the standardized treatment of leukemia, myeloma, lymphoma, aplastic anemia, and other hematological diseases. We also have developed various types of cell therapy techniques, including hematopoietic stem cell transplantation, CAR-T cell therapy, cord blood stem cell transplantation , mesenchymal stem cell therapy, and other novel and advanced treatment methods. We have formed a multidisciplinary team (MDT) with the Intensive Care Unit for elaborate management and comprehensive treatment for the patients with hematological diseases, who experience life-threatening complications. Our Hematology-ICU team specializes in handling complex complications, such as sepsis, hemophagocytic syndrome, as well as graft-versus-host disease and thrombotic microangiopathy, and has significantly reduced the mortality rates and improved overall survival rates of patients. During the early stages, our doctors received systematic training from Loma Linda University Health in the United States. Now, we have developed a standardizing system of diagnosis, management and treatment of hematological diseases in line with international standards. Relying on the molecular diagnostic techniques of the Pathology Department, a National Key Specialty, we have established the first China-US Collaborative Lymphoma Center in Zhejiang province to promote precise diagnosis and individualized treatment of lymphoma. In September 2017, SRRSH became the first member of Mayo Clinic Care Network in China, with the myeloma center in hematology department as a key collaborative project. Through direct cooperation with Mayo Clinic, the department provides advanced, comprehensive, and individualized diagnosis and management for refractory and/or relapsed myeloma patients in line with medical care from the world's best instituion.

The department currently operates at three Campuses: Qingchun Campus, Grand Canal Campus, and Shaoxing Campus, with a total of over 100 approved beds. Each campus has specialized outpatient clinics. The department is recognized as a key medical specialty in Zhejiang Province (Hematology) and one of the first Residency Standardized Training Bases established by the National Health Commission. It is authorized to offer master's and doctoral degree in hematology. The department has 1 doctoral supervisor and other 11 physicians, all of whom hold doctoral or master's degrees. It has an excellent clinical, research and teaching group with strong medical ethics and experienced skills.

Precise and Stratified Treatment for Multiple Myeloma and Lymphoma

Comprehensive Treatment for Refractory Leukemia

Hematopoietic Stem Cell Transplantation

CAR-T Cell Therapy

Umbilical Cord Blood Stem Cell Transplantation

Mesenchymal Stem Cell Transplantation

MDT for  hematological diseases with life-threatening complications

MDT for Cardiac Amyloidosis

National Residency Standardized Training Base

China-US Multiple Myeloma Diagnosis and Treatment Center

Key Medical Specialty in Zhejiang Province (Hematology)

Since 2018, the department has been awarded 6 projects funded by the National 

Natural Science Foundation of China, and one key project funded by the National 

Natural Science Foundation of Zhejiang Province. More than 30 peer-reviewed papers (SCI) have been published.